|

Evaluating the Impact of Different Methods of HPV DNA Testing for Cervical Cancer Screening in Primary Care Settings

RECRUITINGN/ASponsored by National Healthcare Group Polyclinics
Actively Recruiting
PhaseN/A
SponsorNational Healthcare Group Polyclinics
Started2024-08-05
Est. completion2026-12
Eligibility
Age30 Years – 69 Years
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06528184

Summary

Primary objective of the study is to determine the extent that offering of self-sampling in addition to clinician-sampling Human Papillomavirus (HPV) DNA testing will increase detection of HPV DNA through an increase in uptake rates of cervical cancer screening as compared to offering clinician-sampling HPV DNA testing alone. The hypothesis is that offering additional self-sampling will increase the detection of high-risk HPV DNA by at least 7.7%.

Eligibility

Age: 30 Years – 69 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* 30-69 years old female Singapore citizens
* Due for cervical cancer screening
* Engaged in sexual intercourse before
* Able to give informed consent
* Able to read and communicate in English, Chinese or Malay

Exclusion Criteria:

* Virgo intacta
* Pregnancy
* History of cervical cancer, precancerous cervical lesions and total hysterectomy

Conditions2

CancerUterine Cervical Neoplasms

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.